2 assets in Obesity Due To Pro-Opiomelanocortin Deficiency

Therapeutic assets addressing Obesity Due To Pro-Opiomelanocortin Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Setmelanotide Obesity Due To Pro-Opiomelanocortin Deficiency	Rhythm Pharmaceuticals, Inc.	P3	BB (71)
lb54640 Obesity Due To Pro-Opiomelanocortin Deficiency	LG Chem	P2	NR ()